Montclair, New Jersey Clinical Trials

A listing of Montclair, New Jersey clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 52 clinical trials
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated Nonsquamous NSCLC

This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung cancer (NSCLC). The study primary endpoints are …

adjuvant therapy
carboplatin
ros1
measurable disease
stage iv non-small cell lung cancer
New Jersey Cancer Care and Blood Disorders (NJCCBD)
 (2.9 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +27 other locations
TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

This phase II trial studies how well TAS-102 and oxaliplatin work in treating patients with stage IV colon cancer. Drugs used in chemotherapy, such as TAS-102 and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or …

adjuvant therapy
colorectal cancer
bevacizumab
stage iva colon cancer
stage iv colon cancer
Saint Barnabas Medical Center
 (6.2 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +1 other locations
Suicide Prevention for Patients With Chronic Pain

Patients with chronic pain and moderate suicide risk (n=60) will be randomized to receive remote-PST or remote-supportive psychotherapy. We will assess problem-solving deficits through self-report, objective neuropsychological assessment and caregiver report. We have used an adaptive design so that if there is strong evidence for target engagement, we will continue …

chronic widespread pain
suicidal
suicide prevention
suicide
amplified musculoskeletal pain syndrome
VA NJHCS
 (3.9 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI  

The objective of the proposed work is to determine whether administration for 12 months of romosozumab followed by 12 months of denosumab will maintain bone mass at the knee in subjects with subacute SCI compared to 24 months of denosumab administration alone.

Kessler Institute for Rehabilitation
 (1.5 away)
  • 0 views
  • 14 Mar, 2022
  • +1 other locations
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI test  

The objective of the proposed work is to determine whether administration for 12 months of romosozumab followed by 12 months of denosumab will maintain bone mass at the knee in subjects with subacute SCI compared to 24 months of denosumab administration alone.

Accepts healthy volunteers
Kessler Institute for Rehabilitation
 (1.5 away)
  • 0 views
  • 14 Mar, 2022
  • +1 other locations
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The …

gaucher disease
eliglustat
deficiency
imiglucerase
Investigational Site Number 840057
 (6.5 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +208 other locations
Mucopolysaccharidosis I (MPS I) Registry

The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients …

Investigational Site Number 840057
 (6.5 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +124 other locations
Pompe Disease Registry

The Pompe Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Pompe disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives …

deficiency
glycogen storage disease type ii
gaa gene
myozyme
replacement therapy
Investigational Site Number 840057
 (6.5 away) Contact site
  • 0 views
  • 22 Dec, 2020
  • +168 other locations
Fabry Disease Registry & Pregnancy Sub-registry

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The primary …

fabrazyme
agalsidase beta
deficiency
alpha-galactosidase
fabry's disease
Investigational Site Number 840057
 (6.5 away) Contact site
  • 0 views
  • 22 Dec, 2020
  • +125 other locations
BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

The BESPOKE CRC study will prospectively enroll patients who have undergone surgery for stage II or III colorectal cancer (CRC) and who have residual formalin-fixed paraffin-embedded (FFPE) tissue available will provide FFPE and whole blood samples. Patients will receive SIGNATERA test results and may be recommended for adjuvant chemotherapy or …

colorectal cancer
adjuvant chemotherapy
adenocarcinoma of colon
formalin-fixed paraffin-embedded
adenocarcinoma
New Jersey Cancer Care
 (2.9 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +16 other locations